Samsung Bioepis mulling purchase of Biogen's biosimilars unit: reports
并购上市批准
Samsung Bioepis has been in talks to take over Biogen's biosimilars business, according to industry sources cited in South Korean media reports. Sources indicated that through a potential deal, estimated to be worth below KRW 1 trillion ($768 million), Samsung Bioepis is looking to secure a direct sales network in the US and Europe.
Biogen said earlier this year alongside its fourth-quarter financial results that a formal process was under way to evaluate strategic options for the unit, which posted $751 million in revenue in 2022. Last week, the company reported that its biosimilar sales were essentially flat in the second quarter at $195 million. The latest rumours come amid ongoing restructuring efforts by Biogen, including the loss of 1000 more jobs by 2025, to trim costs as it continues with the launch of the Alzheimer's disease drug Leqembi in the US.
Biogen initially took a 15% stake in Samsung Bioepis when it was established as a joint venture with Samsung Biologics in 2012. It boosted its holding to almost 50% in 2018, until Samsung Biologics acquired Biogen's stake last year through a $2.3-billion deal. Despite no longer holding shares, Biogen has remained a partner responsible for sales of Samsung Bioepis' biosimilar products, including Benepali (etanercept), Imraldi (adalimumab), Flixabi (infliximab) and Byooviz (ranibizumab). It also owns rights to Bio-Thera Solutions' BAT1806, a biosimilar referencing Roche's Actemra (tocilizumab).
In a statement, a Samsung Bioepis official said that "when it comes to the acquisition, nothing has been set," and also denied news reports that the company had completed due diligence. "We are reviewing various strategies to secure our biosimilar production capability at a global level and are now focusing on expanding our R&D on competitive pipelines and our sales networks," the official said.
Meanwhile, Samsung Bioepis' commercial partner Organon recently began US sales of Hadlima, a biosimilar referencing AbbVie's Humira (adalimumab). Earlier this week, Samsung Bioepis and Organon said that its studies of Hadlima, also known as SB5, showed that the biosimilar can be interchangeable with Humira. An official at Samsung Bioepis indicated that an interchangeability designation would be sought from the FDA soon.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。